Open access · CC-BY
via OpenAlex
Imaging alpha-synuclein pathology in Parkinson’s disease
Neural Regeneration Research · 2025 · ▲ 3 citations
Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. The clinical manifestations of PD include motor symptoms, such as bradykinesia, resting tremor, rigidity, and nonmotor symptoms, which include disturbances in sleep, gastrointestinal function, and olfaction. PD misdiagnosis rates have been reported to reach approximately 30%, partly owing to the heterogeneity of parkinsonism with non-PD pathologies, and the differential diagnosis of PD from neurodegenerative diseases such as multiple systemic atrophy (MSA) and progressive supranuclear palsy poses another unmet need. These nonmotor symptoms may emerge more than a decade prior to the onset of motor impairments. Pathologically, PD is characterized by the accumulation of Lewy bodies (LBs), which are composed of misfolded alpha-synuclein, and the early loss of dopaminergic neurons. Recent studies have introduced two biomarker-based systems for PD research: the SyNeurGe system and the neuronal alpha-synuclein disease integrated staging system (Höglinger et al., 2024; Simuni et al., 2024). Misfolded alpha-synuclein has been shown to spread between cells, serving as a template for further alpha-synuclein misfolding. Although the precise etiological role of alpha-synuclein in PD has not been fully elucidated, a recent study has revealed heterogeneity in the trajectories of alpha-synuclein pathology in PD and the toxicity of alpha-synuclein especially soluble aggregates (Mastenbroek et al., 2024). Currently, there are several clinical trials targeting alpha-synuclein as disease modifying treatments of PD, either by using active or passive immunotherapy, by preventing alpha-synuclein aggregation, or by disaggregation of existing complexes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.4103/nrr.nrr-d-24-01348
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Ni, R. (2025). Imaging alpha-synuclein pathology in Parkinson’s disease. <em>Neural Regeneration Research</em>. https://doi.org/10.4103/nrr.nrr-d-24-01348
Vancouver
Ni R. Imaging alpha-synuclein pathology in Parkinson’s disease. Neural Regeneration Research. 2025. doi:10.4103/nrr.nrr-d-24-01348.
BibTeX
@article{ruiqing2025Imagin,
title = {Imaging alpha-synuclein pathology in Parkinson’s disease},
author = {Ruiqing Ni},
journal = {Neural Regeneration Research},
year = {2025},
doi = {10.4103/nrr.nrr-d-24-01348},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Brain 2023
Open access · CC-BY
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease
Life 2021
Open access · CC-BY
The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease
npj Parkinson s Disease 2022
Open access · CC-BY
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
Frontiers in Aging 2025
Open access · CC-BY
Pathogenic synergy: dysfunctional mitochondria and neuroinflammation in neurodegenerative diseases associated with aging
Frontiers in Molecular Neuroscience 2019
Open access · CC-BY
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Molecular Neurodegeneration 2011
Open access · CC-BY